Compounds > 2-amino-6-methylpyrimidin-4-one
Page last updated: 2024-10-15

2-amino-6-methylpyrimidin-4-one

Description

2-amino-6-methylpyrimidin-4-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135402055
CHEMBL ID391757
CHEBI ID58959
CHEBI ID499903
SCHEMBL ID94556
MeSH IDM0559353

Synonyms (94)

Synonym
chebi:58959 ,
AC-2389
nsc 23662
nsc 7893
nsc 41833
nsc 13145
einecs 223-612-1
ai3-08094
BB 0243412
2-amino-6-methyl-3h-pyrimidin-4-one
k7za6h32g8 ,
unii-k7za6h32g8
nsc-7893
4-methylisocytosine
mecytosine
superacil
4(1h)-pyrimidinone, 2-amino-6-methyl-
6-methylisocytosine
nsc7893
2-amino-6-methylpyrimidin-4-ol
3977-29-5
superacyl
2-amino-6-methyl-4-pyrimidinol
2-amino-4-hydroxy-6-methylpyrimidine ,
nsc-41833
mls000737047 ,
nsc41833
nsc23662
nsc-23662
SDCCGMLS-0065525.P001
AG-670/25003504
2-amino-6-methylpyrimidin-4(3h)-one
nsc13145
nsc-13145
2-amino-6-methyl-pyrimidin-4-ol
2-amino-6-methyl-4-pyrimidol
2-amino-4-hydroxy-6-methylpyrimidine, 98%
smr000394003
A1204
CHEMBL391757
kwxipeykzkiakr-uhfffaoysa-
inchi=1/c5h7n3o/c1-3-2-4(9)8-5(6)7-3/h2h,1h3,(h3,6,7,8,9)
2-amino-6-methyl-1h-pyrimidin-4-one
CHEBI:499903
AKOS002317139
AKOS003587375
2-amino-6-methylpyrimidin-4-ol;2-amino-6-methylpyrimidin-4(1h)-one
A6638
NCGC00246942-01
HMS2743N05
2-amino-6-methyl-1,4-dihydropyrimidin-4-one
2-amino-4-methyl-6-hydroxypyrimidine
2-amino-6-methylhydropyrimidin-4-one
2-amino-6-hydroxy-4-methylpyrimidine
2-amino-6-methylpyrimidin-4(1h)-one
BP-12838
FT-0611113
AM20100050
F0827-0314
SCHEMBL94556
cid_1532
2-azanyl-6-methyl-1h-pyrimidin-4-one
bdbm73774
2-amino-6-methyl-4-pyrimidone
2-amino-6-methyl-4-pyrimidinone
2-amino-4-hydroxy-6-methyl-pyrimidine
2-amino-6-methylpyrimidin-4-one
6-methyl-isocytosine
6-methyl-iso cytosine
2 -amino-4-hydroxy-6-methyl-pyrimidine
AKOS024284331
W-106404
2-amino-4-oxo-6-methylpyrimidine
4-pyrimidinol, 2-amino-6-methyl-
2-amino-6-methyl-3,4-dihydropyrimidin-4-one
Z1530057780
F0001-1117
DTXSID90192847
mfcd00006095
GS-6812
2-imino4-hydroxy-6-methylpyrimidine
SY012702
2-imino-6-methyl-2,3-dihydro-1h-pyrimidin-4-one
2-amino-6-methyl-4-oxopyrimidine
4(3h)-pyrimidinone, 2-amino-6-methyl-
4-hydroxy-6-methyl-2-pyrimidinamine
2-amino-6-methyl-4(1h)-pyrimidinone
Q27126361
BCP26445
2-amino-4-methyl-1h-pyrimidin-6-one
EN300-100626
CS-0030573
mfcd00233528
SB57739
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
hydroxypyrimidine
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID303945Binding affinity to BACE1 expressed in HEK293 cells by Biocore ISA2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
AID303944Binding affinity to BACE1 expressed in HEK293 cells assessed as free enzyme at 1 mM after 10 mins by Biocore ISA2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
AID303946Binding affinity to endothiapepsin by Biocore ISA2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cytosine
[no description available]		2.1310aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
om99-2
OM99-2: eight-residue memapsin 2 inhibitor; structure in first source		2.0310
2,4-diaminohypoxanthine
2,4-diaminohypoxanthine: do not confuse abbreviation DAHP with various dehydro-deoxy-arabino-heptulosonic acid phosphates which also use DAHP; RN given refers to parent cpd; structure		2.0610hydroxypyrimidine
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		2.4920
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510